Navigation Links
Prozac's target revealed

Researchers at Cold Spring Harbor Laboratory on Long Island have identified which among several different kinds of cells in the brain is the chief target of the widely prescribed antidepressant Prozac. This discovery might enable a new generation of more specific treatments for depression, with fewer side effects, to be developed.

The findings also lay the foundation for many studies of the factors that control how, when, and where new neurons are generated from stem cells in the brain. Such work could eventually lead to cell replacement therapies for neurodegenerative and other brain disorders including Alzheimer's and Parkinson's disease.

It has been known for some years that Prozac (fluoxetine) is likely to relieve the symptoms of depression by somehow causing more neurons to be present in a particular region of the brain (the "dentate gyrus"). But the origins of these neurons, and how Prozac promotes their existence, have been a mystery until now.

By profiling the telltale marker proteins produced by different kinds of cells in the brains of adult mice, the researchers first defined discrete steps in the complex process, called neurogenesis, that converts unspecialized stem cells into mature, specialized neurons.

Next, knowing that Prozac treatment somehow increases the number of neurons in the brain, the researchers tested which step in the neurogenesis pathway might be stimulated by Prozac. They found that Prozac treatment specifically stimulates the generation of a kind of cells they dubbed "amplifying neural progenitors" or ANPs--the second step in the neurogenesis pathway from stem cells to mature neurons. (Illustration available on request)

The study is published in the published in the Proceedings of the National Academy of Sciences (advance on-line this week, in print on May 23). It was led by Grigori Enikolopov and spearheaded by postdoctoral fellow Juan Manuel Encinas.

To address the controversy surroundin g the use of Prozac in children and in pregnant women, Enikolopov's group is currently testing the effects of the drug on brain neurogenesis in juvenile and pregnant mice. The results of those experiments may provide valuable information for assessing the possible effects of Prozac and related drugs on fetal and adolescent brain development.

The researchers are currently using the approach and tools they've developed to explore whether other treatments for depression--including other drugs and deep brain stimulation--act in the same way as Prozac or in different ways. In addition, the scientists are screening for new drugs that expand the production of brain neurons by stimulating ANP cells to multiply.

In collaboration with NASA researchers, experiments are also under way at Cold Spring Harbor Laboratory to assess how neurogenesis in the adult brain might be influenced by long-term, Mission-to-Mars levels of exposure to a particular kind of damaging radiation that's prevalent in space.


'"/>

Source:Cold Spring Harbor Laboratory


Related biology news :

1. New binding target for oncogenic viral protein
2. Ancient olfaction protein is shared by many bugs, offering new pest control target
3. A bacterial genome reveals new targets to combat infectious disease
4. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
5. Researchers identify target for cancer drugs
6. Study reveals candidate targets for anti-retroviral therapeutics
7. MUHC researchers make cancer target breakthrough
8. Future diabetes drugs may target new protein interaction
9. Smart drug targets deadly brain cancer
10. NHGRI targets 12 more organisms for genome sequencing
11. While on trail of dioxin, scientists pinpoint cancer target of green tea
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory ... technical consulting, provides a free webinar on Performing Quality Investigations: Getting ... at 12pm CT at no charge. , Incomplete investigations are still a major ...
(Date:6/22/2016)... 22, 2016 Research and Markets has announced ... report to their offering. ... from $29.3 billion in 2013. The market is expected to grow ... 2015 to 2020, increasing from $50.6 billion in 2015 to $96.6 ... during the forecast period (2015 to 2020) are discussed. As well, ...
Breaking Biology Technology: